Compare LPA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LPA | KZIA |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.9M | 100.8M |
| IPO Year | 2023 | 2002 |
| Metric | LPA | KZIA |
|---|---|---|
| Price | $2.85 | $10.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 18.6K | ★ 198.1K |
| Earning Date | 05-13-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.04 | $4.86 |
| 52 Week High | $8.08 | $17.40 |
| Indicator | LPA | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 41.37 | 41.11 |
| Support Level | $2.84 | $5.71 |
| Resistance Level | $3.33 | $14.57 |
| Average True Range (ATR) | 0.18 | 1.07 |
| MACD | -0.03 | -0.36 |
| Stochastic Oscillator | 29.05 | 11.06 |
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has four operating segments, based on geographic regions, consisting of Colombia, Peru, Mexico and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.